The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Empagliflozin Drug Market Research Report 2025
Synopsis
The global market for Empagliflozin Drug was valued at US$ 19490 million in the year 2024 and is projected to reach a revised size of US$ 51550 million by 2031, growing at a CAGR of 15.7% during the forecast period.
Empagliflozin is an oral antidiabetic drug that belongs to the class of SGLT2 (sodium-glucose co-transporter 2) inhibitors. It works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine, thereby lowering blood sugar levels. In addition to managing type 2 diabetes, empagliflozin has also been shown to reduce the risk of cardiovascular death in patients with heart failure or those at high risk of cardiovascular events.
North American market for Empagliflozin Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Empagliflozin Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Empagliflozin Drug include Boehringer Ingelheim, Sichuan Kelun Pharmaceutical, OriFarm, PARANOVA PACK, Jiangsu Wanbang, Zhengda Tianqing, EurimPharm Arzneimittel, ABACUS MEDICINE, Jiangsu Hausen, Lupin Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Empagliflozin Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Empagliflozin Drug.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Empagliflozin Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The Empagliflozin Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Empagliflozin Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Empagliflozin Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
Sichuan Kelun Pharmaceutical
OriFarm
PARANOVA PACK
Jiangsu Wanbang
Zhengda Tianqing
EurimPharm Arzneimittel
ABACUS MEDICINE
Jiangsu Hausen
Lupin Laboratories
Segment by Type
Single-ingredient
Combination
Segment by Application
Hospitals
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Empagliflozin Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Empagliflozin Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Empagliflozin Drug was valued at US$ 19490 million in the year 2024 and is projected to reach a revised size of US$ 51550 million by 2031, growing at a CAGR of 15.7% during the forecast period.
Empagliflozin is an oral antidiabetic drug that belongs to the class of SGLT2 (sodium-glucose co-transporter 2) inhibitors. It works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine, thereby lowering blood sugar levels. In addition to managing type 2 diabetes, empagliflozin has also been shown to reduce the risk of cardiovascular death in patients with heart failure or those at high risk of cardiovascular events.
North American market for Empagliflozin Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Empagliflozin Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Empagliflozin Drug include Boehringer Ingelheim, Sichuan Kelun Pharmaceutical, OriFarm, PARANOVA PACK, Jiangsu Wanbang, Zhengda Tianqing, EurimPharm Arzneimittel, ABACUS MEDICINE, Jiangsu Hausen, Lupin Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Empagliflozin Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Empagliflozin Drug.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Empagliflozin Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The Empagliflozin Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Empagliflozin Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Empagliflozin Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Boehringer Ingelheim
Sichuan Kelun Pharmaceutical
OriFarm
PARANOVA PACK
Jiangsu Wanbang
Zhengda Tianqing
EurimPharm Arzneimittel
ABACUS MEDICINE
Jiangsu Hausen
Lupin Laboratories
Segment by Type
Single-ingredient
Combination
Segment by Application
Hospitals
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Empagliflozin Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Empagliflozin Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Empagliflozin Drug Market Overview
1.1 Product Definition
1.2 Empagliflozin Drug by Type
1.2.1 Global Empagliflozin Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Single-ingredient
1.2.3 Combination
1.3 Empagliflozin Drug by Application
1.3.1 Global Empagliflozin Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Empagliflozin Drug Market Size Estimates and Forecasts
1.4.1 Global Empagliflozin Drug Revenue 2020-2031
1.4.2 Global Empagliflozin Drug Sales 2020-2031
1.4.3 Global Empagliflozin Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Empagliflozin Drug Market Competition by Manufacturers
2.1 Global Empagliflozin Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Empagliflozin Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Empagliflozin Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Empagliflozin Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Empagliflozin Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Empagliflozin Drug, Product Type & Application
2.7 Global Key Manufacturers of Empagliflozin Drug, Date of Enter into This Industry
2.8 Global Empagliflozin Drug Market Competitive Situation and Trends
2.8.1 Global Empagliflozin Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Empagliflozin Drug Players Market Share by Revenue
2.8.3 Global Empagliflozin Drug Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Empagliflozin Drug Market Scenario by Region
3.1 Global Empagliflozin Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Empagliflozin Drug Sales by Region: 2020-2031
3.2.1 Global Empagliflozin Drug Sales by Region: 2020-2025
3.2.2 Global Empagliflozin Drug Sales by Region: 2026-2031
3.3 Global Empagliflozin Drug Revenue by Region: 2020-2031
3.3.1 Global Empagliflozin Drug Revenue by Region: 2020-2025
3.3.2 Global Empagliflozin Drug Revenue by Region: 2026-2031
3.4 North America Empagliflozin Drug Market Facts & Figures by Country
3.4.1 North America Empagliflozin Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Empagliflozin Drug Sales by Country (2020-2031)
3.4.3 North America Empagliflozin Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Empagliflozin Drug Market Facts & Figures by Country
3.5.1 Europe Empagliflozin Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Empagliflozin Drug Sales by Country (2020-2031)
3.5.3 Europe Empagliflozin Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Empagliflozin Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Empagliflozin Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Empagliflozin Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Empagliflozin Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Empagliflozin Drug Market Facts & Figures by Country
3.7.1 Latin America Empagliflozin Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Empagliflozin Drug Sales by Country (2020-2031)
3.7.3 Latin America Empagliflozin Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Empagliflozin Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Empagliflozin Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Empagliflozin Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Empagliflozin Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Empagliflozin Drug Sales by Type (2020-2031)
4.1.1 Global Empagliflozin Drug Sales by Type (2020-2025)
4.1.2 Global Empagliflozin Drug Sales by Type (2026-2031)
4.1.3 Global Empagliflozin Drug Sales Market Share by Type (2020-2031)
4.2 Global Empagliflozin Drug Revenue by Type (2020-2031)
4.2.1 Global Empagliflozin Drug Revenue by Type (2020-2025)
4.2.2 Global Empagliflozin Drug Revenue by Type (2026-2031)
4.2.3 Global Empagliflozin Drug Revenue Market Share by Type (2020-2031)
4.3 Global Empagliflozin Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Empagliflozin Drug Sales by Application (2020-2031)
5.1.1 Global Empagliflozin Drug Sales by Application (2020-2025)
5.1.2 Global Empagliflozin Drug Sales by Application (2026-2031)
5.1.3 Global Empagliflozin Drug Sales Market Share by Application (2020-2031)
5.2 Global Empagliflozin Drug Revenue by Application (2020-2031)
5.2.1 Global Empagliflozin Drug Revenue by Application (2020-2025)
5.2.2 Global Empagliflozin Drug Revenue by Application (2026-2031)
5.2.3 Global Empagliflozin Drug Revenue Market Share by Application (2020-2031)
5.3 Global Empagliflozin Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Empagliflozin Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Sichuan Kelun Pharmaceutical
6.2.1 Sichuan Kelun Pharmaceutical Company Information
6.2.2 Sichuan Kelun Pharmaceutical Description and Business Overview
6.2.3 Sichuan Kelun Pharmaceutical Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sichuan Kelun Pharmaceutical Empagliflozin Drug Product Portfolio
6.2.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates
6.3 OriFarm
6.3.1 OriFarm Company Information
6.3.2 OriFarm Description and Business Overview
6.3.3 OriFarm Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 OriFarm Empagliflozin Drug Product Portfolio
6.3.5 OriFarm Recent Developments/Updates
6.4 PARANOVA PACK
6.4.1 PARANOVA PACK Company Information
6.4.2 PARANOVA PACK Description and Business Overview
6.4.3 PARANOVA PACK Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 PARANOVA PACK Empagliflozin Drug Product Portfolio
6.4.5 PARANOVA PACK Recent Developments/Updates
6.5 Jiangsu Wanbang
6.5.1 Jiangsu Wanbang Company Information
6.5.2 Jiangsu Wanbang Description and Business Overview
6.5.3 Jiangsu Wanbang Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Jiangsu Wanbang Empagliflozin Drug Product Portfolio
6.5.5 Jiangsu Wanbang Recent Developments/Updates
6.6 Zhengda Tianqing
6.6.1 Zhengda Tianqing Company Information
6.6.2 Zhengda Tianqing Description and Business Overview
6.6.3 Zhengda Tianqing Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Zhengda Tianqing Empagliflozin Drug Product Portfolio
6.6.5 Zhengda Tianqing Recent Developments/Updates
6.7 EurimPharm Arzneimittel
6.7.1 EurimPharm Arzneimittel Company Information
6.7.2 EurimPharm Arzneimittel Description and Business Overview
6.7.3 EurimPharm Arzneimittel Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 EurimPharm Arzneimittel Empagliflozin Drug Product Portfolio
6.7.5 EurimPharm Arzneimittel Recent Developments/Updates
6.8 ABACUS MEDICINE
6.8.1 ABACUS MEDICINE Company Information
6.8.2 ABACUS MEDICINE Description and Business Overview
6.8.3 ABACUS MEDICINE Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 ABACUS MEDICINE Empagliflozin Drug Product Portfolio
6.8.5 ABACUS MEDICINE Recent Developments/Updates
6.9 Jiangsu Hausen
6.9.1 Jiangsu Hausen Company Information
6.9.2 Jiangsu Hausen Description and Business Overview
6.9.3 Jiangsu Hausen Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Jiangsu Hausen Empagliflozin Drug Product Portfolio
6.9.5 Jiangsu Hausen Recent Developments/Updates
6.10 Lupin Laboratories
6.10.1 Lupin Laboratories Company Information
6.10.2 Lupin Laboratories Description and Business Overview
6.10.3 Lupin Laboratories Empagliflozin Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Lupin Laboratories Empagliflozin Drug Product Portfolio
6.10.5 Lupin Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Empagliflozin Drug Industry Chain Analysis
7.2 Empagliflozin Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Empagliflozin Drug Production Mode & Process Analysis
7.4 Empagliflozin Drug Sales and Marketing
7.4.1 Empagliflozin Drug Sales Channels
7.4.2 Empagliflozin Drug Distributors
7.5 Empagliflozin Drug Customer Analysis
8 Empagliflozin Drug Market Dynamics
8.1 Empagliflozin Drug Industry Trends
8.2 Empagliflozin Drug Market Drivers
8.3 Empagliflozin Drug Market Challenges
8.4 Empagliflozin Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Empagliflozin Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Empagliflozin Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Empagliflozin Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Empagliflozin Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Empagliflozin Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Empagliflozin Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Empagliflozin Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Empagliflozin Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Empagliflozin Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Empagliflozin Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Empagliflozin Drug, Product Type & Application
Table 12. Global Key Manufacturers of Empagliflozin Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Empagliflozin Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Empagliflozin Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Empagliflozin Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Empagliflozin Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Empagliflozin Drug Sales Market Share by Region (2020-2025)
Table 19. Global Empagliflozin Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Empagliflozin Drug Sales Market Share by Region (2026-2031)
Table 21. Global Empagliflozin Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Empagliflozin Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Empagliflozin Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Empagliflozin Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Empagliflozin Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Empagliflozin Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Empagliflozin Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Empagliflozin Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Empagliflozin Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Empagliflozin Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Empagliflozin Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Empagliflozin Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Empagliflozin Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Empagliflozin Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Empagliflozin Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Empagliflozin Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Empagliflozin Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Empagliflozin Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Empagliflozin Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Empagliflozin Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Empagliflozin Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Empagliflozin Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Empagliflozin Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Empagliflozin Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Empagliflozin Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Empagliflozin Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Empagliflozin Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Empagliflozin Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Empagliflozin Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Empagliflozin Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Empagliflozin Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Empagliflozin Drug Sales Market Share by Type (2020-2025)
Table 53. Global Empagliflozin Drug Sales Market Share by Type (2026-2031)
Table 54. Global Empagliflozin Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Empagliflozin Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Empagliflozin Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Empagliflozin Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Empagliflozin Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Empagliflozin Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Empagliflozin Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Empagliflozin Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Empagliflozin Drug Sales Market Share by Application (2020-2025)
Table 63. Global Empagliflozin Drug Sales Market Share by Application (2026-2031)
Table 64. Global Empagliflozin Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Empagliflozin Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Empagliflozin Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Empagliflozin Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Empagliflozin Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Empagliflozin Drug Price (US$/Unit) by Application (2026-2031)
Table 70. Boehringer Ingelheim Company Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Boehringer Ingelheim Empagliflozin Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Sichuan Kelun Pharmaceutical Company Information
Table 76. Sichuan Kelun Pharmaceutical Description and Business Overview
Table 77. Sichuan Kelun Pharmaceutical Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Sichuan Kelun Pharmaceutical Empagliflozin Drug Product
Table 79. Sichuan Kelun Pharmaceutical Recent Developments/Updates
Table 80. OriFarm Company Information
Table 81. OriFarm Description and Business Overview
Table 82. OriFarm Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. OriFarm Empagliflozin Drug Product
Table 84. OriFarm Recent Developments/Updates
Table 85. PARANOVA PACK Company Information
Table 86. PARANOVA PACK Description and Business Overview
Table 87. PARANOVA PACK Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. PARANOVA PACK Empagliflozin Drug Product
Table 89. PARANOVA PACK Recent Developments/Updates
Table 90. Jiangsu Wanbang Company Information
Table 91. Jiangsu Wanbang Description and Business Overview
Table 92. Jiangsu Wanbang Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Jiangsu Wanbang Empagliflozin Drug Product
Table 94. Jiangsu Wanbang Recent Developments/Updates
Table 95. Zhengda Tianqing Company Information
Table 96. Zhengda Tianqing Description and Business Overview
Table 97. Zhengda Tianqing Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Zhengda Tianqing Empagliflozin Drug Product
Table 99. Zhengda Tianqing Recent Developments/Updates
Table 100. EurimPharm Arzneimittel Company Information
Table 101. EurimPharm Arzneimittel Description and Business Overview
Table 102. EurimPharm Arzneimittel Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. EurimPharm Arzneimittel Empagliflozin Drug Product
Table 104. EurimPharm Arzneimittel Recent Developments/Updates
Table 105. ABACUS MEDICINE Company Information
Table 106. ABACUS MEDICINE Description and Business Overview
Table 107. ABACUS MEDICINE Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. ABACUS MEDICINE Empagliflozin Drug Product
Table 109. ABACUS MEDICINE Recent Developments/Updates
Table 110. Jiangsu Hausen Company Information
Table 111. Jiangsu Hausen Description and Business Overview
Table 112. Jiangsu Hausen Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Jiangsu Hausen Empagliflozin Drug Product
Table 114. Jiangsu Hausen Recent Developments/Updates
Table 115. Lupin Laboratories Company Information
Table 116. Lupin Laboratories Description and Business Overview
Table 117. Lupin Laboratories Empagliflozin Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Lupin Laboratories Empagliflozin Drug Product
Table 119. Lupin Laboratories Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Empagliflozin Drug Distributors List
Table 123. Empagliflozin Drug Customers List
Table 124. Empagliflozin Drug Market Trends
Table 125. Empagliflozin Drug Market Drivers
Table 126. Empagliflozin Drug Market Challenges
Table 127. Empagliflozin Drug Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Empagliflozin Drug
Figure 2. Global Empagliflozin Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Empagliflozin Drug Market Share by Type: 2024 & 2031
Figure 4. Single-ingredient Product Picture
Figure 5. Combination Product Picture
Figure 6. Global Empagliflozin Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 7. Global Empagliflozin Drug Market Share by Application: 2024 & 2031
Figure 8. Hospitals
Figure 9. Retail Pharmacy
Figure 10. Others
Figure 11. Global Empagliflozin Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Empagliflozin Drug Market Size (2020-2031) & (US$ Million)
Figure 13. Global Empagliflozin Drug Sales (2020-2031) & (K Units)
Figure 14. Global Empagliflozin Drug Average Price (US$/Unit) & (2020-2031)
Figure 15. Empagliflozin Drug Report Years Considered
Figure 16. Empagliflozin Drug Sales Share by Manufacturers in 2024
Figure 17. Global Empagliflozin Drug Revenue Share by Manufacturers in 2024
Figure 18. Global 5 and 10 Largest Empagliflozin Drug Players: Market Share by Revenue in Empagliflozin Drug in 2024
Figure 19. Empagliflozin Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 20. Global Empagliflozin Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 21. North America Empagliflozin Drug Sales Market Share by Country (2020-2031)
Figure 22. North America Empagliflozin Drug Revenue Market Share by Country (2020-2031)
Figure 23. United States Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 24. Canada Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Europe Empagliflozin Drug Sales Market Share by Country (2020-2031)
Figure 26. Europe Empagliflozin Drug Revenue Market Share by Country (2020-2031)
Figure 27. Germany Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. France Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. U.K. Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Italy Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Russia Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Asia Pacific Empagliflozin Drug Sales Market Share by Region (2020-2031)
Figure 33. Asia Pacific Empagliflozin Drug Revenue Market Share by Region (2020-2031)
Figure 34. China Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Japan Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. South Korea Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. India Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Australia Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. China Taiwan Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Latin America Empagliflozin Drug Sales Market Share by Country (2020-2031)
Figure 42. Latin America Empagliflozin Drug Revenue Market Share by Country (2020-2031)
Figure 43. Mexico Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Brazil Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Argentina Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Colombia Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Empagliflozin Drug Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Empagliflozin Drug Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Empagliflozin Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Empagliflozin Drug by Type (2020-2031)
Figure 53. Global Revenue Market Share of Empagliflozin Drug by Type (2020-2031)
Figure 54. Global Empagliflozin Drug Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Empagliflozin Drug by Application (2020-2031)
Figure 56. Global Revenue Market Share of Empagliflozin Drug by Application (2020-2031)
Figure 57. Global Empagliflozin Drug Price (US$/Unit) by Application (2020-2031)
Figure 58. Empagliflozin Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
